152 related articles for article (PubMed ID: 29107104)
1. Novel recurrence risk stratification of resected pancreatic neuroendocrine tumor.
Gao H; Liu L; Wang W; Xu H; Jin K; Wu C; Qi Z; Zhang S; Liu C; Xu J; Ni Q; Yu X
Cancer Lett; 2018 Jan; 412():188-193. PubMed ID: 29107104
[TBL] [Abstract][Full Text] [Related]
2. Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors: Improving Its Prognostic Value for Recurrence of Disease.
Lopez-Aguiar AG; Ethun CG; Postlewait LM; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Sarmiento JM; Kooby DA; Staley CA; Maithel SK; Cardona K
Ann Surg Oncol; 2018 Jan; 25(1):290-298. PubMed ID: 29079920
[TBL] [Abstract][Full Text] [Related]
3. Novel scoring system for recurrence risk classification of surgically resected G1/2 pancreatic neuroendocrine tumors - Retrospective cohort study.
Zou S; Jiang Y; Wang W; Zhan Q; Deng X; Shen B
Int J Surg; 2020 Feb; 74():86-91. PubMed ID: 31926324
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for short recurrence-free survival after resection of pancreatic neuroendocrine tumor (PanNET) liver metastases: which patients should undergo resection?
Masui T; Nagai K; Anazawa T; Kasai Y; Sato A; Nakano K; Uchida Y; Yogo A; Kawaguchi Y; Takaori K; Uemoto S
Scand J Gastroenterol; 2020 Apr; 55(4):479-484. PubMed ID: 32223573
[No Abstract] [Full Text] [Related]
5. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
[TBL] [Abstract][Full Text] [Related]
6. Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67.
Genç CG; Falconi M; Partelli S; Muffatti F; van Eeden S; Doglioni C; Klümpen HJ; van Eijck CHJ; Nieveen van Dijkum EJM
Ann Surg Oncol; 2018 Aug; 25(8):2467-2474. PubMed ID: 29789972
[TBL] [Abstract][Full Text] [Related]
7. A Prognostic Scoring System for the Prediction of Metastatic Recurrence Following Curative Resection of Pancreatic Neuroendocrine Tumors.
Sho S; Court CM; Winograd P; Toste PA; Pisegna JR; Lewis M; Donahue TR; Hines OJ; Reber HA; Dawson DW; Tomlinson JS
J Gastrointest Surg; 2019 Jul; 23(7):1392-1400. PubMed ID: 30353489
[TBL] [Abstract][Full Text] [Related]
8. Is radical surgery always curative in pancreatic neuroendocrine tumors? A cure model survival analysis.
Ricci C; Casadei R; Taffurelli G; Campana D; Ambrosini V; Pacilio CA; Santini D; Brighi N; Minni F
Pancreatology; 2018 Apr; 18(3):313-317. PubMed ID: 29487026
[TBL] [Abstract][Full Text] [Related]
9. A novel risk factor panel predicts early recurrence in resected pancreatic neuroendocrine tumors.
Wang WQ; Zhang WH; Gao HL; Huang D; Xu HX; Li S; Li TJ; Xu SS; Li H; Long J; Ye LY; Wu CT; Han X; Wang XH; Liu L; Yu XJ
J Gastroenterol; 2021 Apr; 56(4):395-405. PubMed ID: 33742253
[TBL] [Abstract][Full Text] [Related]
10. Predictors of Recurrence and Survival in Patients With Surgically Resected Pancreatic Neuroendocrine Tumors.
Rosenblum RE; Harris CK; Baeg KJ; Starr JA; Brais LK; Stashek KM; Ward SC; Katona BW; Clancy TE; Wisnivesky JP; Kulke MH; Metz DC; Kim MK; Chan JA
Pancreas; 2020 Feb; 49(2):249-254. PubMed ID: 32011530
[TBL] [Abstract][Full Text] [Related]
11. The Postoperative Occurrence or Worsening of Diabetes Mellitus May Increase the Risk of Recurrence in Resected Pancreatic Neuroendocrine Tumors.
de Mestier L; Védie AL; Faron M; Cros J; Rebours V; Hentic O; Do Cao C; Bardet P; Lévy P; Sauvanet A; Ruszniewski P; Hammel P
Neuroendocrinology; 2020; 110(11-12):967-976. PubMed ID: 31791037
[TBL] [Abstract][Full Text] [Related]
12. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications.
Strosberg JR; Cheema A; Weber JM; Ghayouri M; Han G; Hodul PJ; Kvols LK
Ann Surg; 2012 Aug; 256(2):321-5. PubMed ID: 22415420
[TBL] [Abstract][Full Text] [Related]
13. The size of well differentiated pancreatic neuroendocrine tumors correlates with Ki67 proliferative index and is not associated with age.
Partelli S; Muffatti F; Rancoita PMV; Andreasi V; Balzano G; Crippa S; Doglioni C; Rubini C; Zamboni G; Falconi M
Dig Liver Dis; 2019 May; 51(5):735-740. PubMed ID: 30723019
[TBL] [Abstract][Full Text] [Related]
14. Distinct clinicopathological and prognostic features of insulinoma with synchronous distant metastasis.
Gao H; Wang W; Xu H; Wu C; Jin W; Zhang S; Xu J; Ni Q; Yu X; Liu L
Pancreatology; 2019 Apr; 19(3):472-477. PubMed ID: 30850220
[TBL] [Abstract][Full Text] [Related]
15. Prediction of disease recurrence in patients after complete pancreatic NET (PanNET) G2 resection.
Olearska H; Sowa-Staszczak A; Morawiec-Sławek K; Kurzyńska A; Kolasa M; Tkacz E; Szumińska M; Hubalewska-Dydejczyk A; Opalinska M
Endokrynol Pol; 2024; 75(1):102-108. PubMed ID: 38497396
[TBL] [Abstract][Full Text] [Related]
16. The role of lymph node ratio in recurrence after curative surgery for pancreatic endocrine tumours.
Ricci C; Casadei R; Taffurelli G; Buscemi S; D'Ambra M; Monari F; Santini D; Campana D; Tomassetti P; Minni F
Pancreatology; 2013; 13(6):589-93. PubMed ID: 24280574
[TBL] [Abstract][Full Text] [Related]
17. Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections.
Boninsegna L; Panzuto F; Partelli S; Capelli P; Delle Fave G; Bettini R; Pederzoli P; Scarpa A; Falconi M
Eur J Cancer; 2012 Jul; 48(11):1608-15. PubMed ID: 22129889
[TBL] [Abstract][Full Text] [Related]
18. Predictive Value of Chromogranin A and a Pre-Operative Risk Score to Predict Recurrence After Resection of Pancreatic Neuroendocrine Tumors.
Fisher AV; Lopez-Aguiar AG; Rendell VR; Pokrzywa C; Rocha FG; Kanji ZS; Poultsides GA; Makris EA; Dillhoff ME; Beal EW; Fields RC; Panni RZ; Idrees K; Smith PM; Cho CS; Beems MV; Maithel SK; Winslow ER; Abbott DE; Weber SM
J Gastrointest Surg; 2019 Apr; 23(4):651-658. PubMed ID: 30659439
[TBL] [Abstract][Full Text] [Related]
19. Prognostic stratification of metastatic gastroenteropancreatic neuroendocrine neoplasms by 18F-FDG PET: feasibility of a metabolic grading system.
Ezziddin S; Adler L; Sabet A; Pöppel TD; Grabellus F; Yüce A; Fischer HP; Simon B; Höller T; Biersack HJ; Nagarajah J
J Nucl Med; 2014 Aug; 55(8):1260-6. PubMed ID: 24876204
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic neuroendocrine tumors: accurate grading with Ki-67 index on fine-needle aspiration specimens using the WHO 2010/ENETS criteria.
Farrell JM; Pang JC; Kim GE; Tabatabai ZL
Cancer Cytopathol; 2014 Oct; 122(10):770-8. PubMed ID: 25044931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]